Objective
Specific stimulation of MHC class I-restricted cytotoxic T lymphocytes (CTL) responses is a key objective for vaccines against intracellular infections. Epitope repertoires (ER) recognized by CTL are generated by processing antigen in proteasome/TAP-dependent (ER^prot) and alternative proteasome/ TAP-independent (ER^alt) pathways. Many new vaccination strategies prime CTL to alternatively pro-cessed antigens. The consortium targets the analysis of alternative processing of vaccine-relevant antigens from HCV, HBV and malaria plasmodia resulting in peptides for human/murine MHC class I presentation. It will be tested if CTL populations specific for the ER^alt alone, or in combination with CTL recognizing the ER^prot are associated with protection against natural human HBV, HCV and plasmodium infections. The insight into alternative processing will be used to design and test optimised safe vaccines that induce broad CTL immunity also to the ER^alt.
Fields of science
- medical and health scienceshealth sciencesinfectious diseasesmalaria
- medical and health scienceshealth sciencesinfectious diseasesDNA viruseshepatitis B
- medical and health scienceshealth sciencesinfectious diseasesRNA viruseshepatitis C
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- natural sciencesmathematicspure mathematicsarithmeticsprime numbers
Call for proposal
Data not availableFunding Scheme
CSC - Cost-sharing contractsCoordinator
89081 Ulm
Germany
See on map
Participants (3)
75743 Paris
See on map
DD1 5EH Dundee
See on map
1066 Epalinges
See on map